Giancarlo Comi, MD, Vita-Salute San Raffaele University, Milan, Italy, discusses the approaches needed for treatment success in progressive multiple sclerosis (MS). Considering that the available measures for monitoring the evolution of progressive MS and treatment response have limitations, it is crucial to explore better alternatives. Patient-reported outcomes could be the best way to directly monitor the progressive phase of MS. The Patient-Reported Outcomes for MS (PROMS) program, led and coordinated by the European Charcot Foundation and the Multiple Sclerosis International Federation, is trying to validate existing and new patient-reported outcome measures. This interview took place during the 2022 World Congress on Controversies in Neurology (CONy) meeting.
Prof. Comi has received consulting and speaking fees from Novartis, Sanofi Genzyme, Genzyme Corporation, Merck KGgA, Merck Serono SpA, Celgene Group, F. Hoffman-La Roche, Almirall SpA, Janssen.